"The Temple Lung Center helps people with all types of lung disease breathe easier and live more active lives. We are a national leader in diagnosing and treating lung problems, whether you have a common issue like asthma or a complex condition like chronic obstructive pulmonary disease (COPD)."

During the past decade, Temple University Lung Center conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 12 clinical trials were completed, i.e. on average, 109.1% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 6 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Temple University Lung Center" #1 sponsor was "Actelion" with 5 trials, followed by "University of Minnesota" with 5 trials sponsored, "Aeris Therapeutics" with 4 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored and "United Therapeutics" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Temple University Lung Center" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 3 trials as a collaborator, "United States Department of Defense" with 2 trials as a collaborator, "University of Alabama at Birmingham" with 2 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 1 trials as a collaborator and "Ottawa Hospital Research Institute" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Temple University Lung Center" are "Pulmonary Disease, Chronic Obstructive" (6 trials), "Idiopathic Pulmonary Fibrosis" (5 trials), "Pulmonary Hypertension" (4 trials), "Pulmonary Emphysema" (3 trials) and "Chronic Obstructive Pulmonary Disease" (2 trials). Many other conditions were trialed in "Temple University Lung Center" in a lesser frequency.

Most popular intervention types in "Temple University Lung Center" are "Drug" (19 trials), "Other" (4 trials), "Biological" (3 trials), "Device" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "ACT-064992 (macitentan)" (1 trials), "Acthar Gel" (1 trials), "Arformoterol tartrate inhalation solution" (1 trials) and "BLVR System" (1 trials). Other intervention names were less common.

The vast majority of trials in "Temple University Lung Center" are 26 trials for "All" genders.

Currently, there are NaN active trials in "Temple University Lung Center". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Temple University Lung Center, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Temple University Lung Center, 1 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".